Sanofi (NASDAQ:SNY) Receives Consensus Rating of “Hold” from Analysts

Sanofi (NASDAQ:SNY) has been given a consensus rating of “Hold” by the sixteen brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $49.50.

Several brokerages have weighed in on SNY. Royal Bank Of Canada began coverage on Sanofi in a research note on Tuesday, September 8th. They set a “sector perform” rating on the stock. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 29th. Morgan Stanley set a $49.00 price target on Sanofi in a report on Wednesday, July 8th. Finally, Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd.

Institutional Investors Weigh In On Sanofi

Hedge funds and other institutional investors have recently made changes to their positions in the company. Physician Wealth Advisors Inc. grew its holdings in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after purchasing an additional 379 shares during the last quarter. Leonteq Securities AG lifted its stake in Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after purchasing an additional 297 shares during the last quarter. Western Wealth Management LLC bought a new stake in Sanofi in the first quarter worth about $29,000. Fairway Wealth LLC purchased a new position in shares of Sanofi during the first quarter valued at approximately $32,000. Finally, Annis Gardner Whiting Capital Advisors LLC grew its stake in shares of Sanofi by 544.4% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock valued at $34,000 after buying an additional 588 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Price Performance

Sanofi stock opened at $41.18 on Tuesday. The company has a market cap of $99.84 billion, a price-to-earnings ratio of 21.56, a PEG ratio of 1.24 and a beta of 0.35. The firm’s fifty day moving average is $43.64 and its 200 day moving average is $44.24. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. Sanofi has a 52-week low of $40.65 and a 52-week high of $52.68.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business had revenue of $13.36 billion during the quarter. During the same period in the previous year, the business earned $3.24 earnings per share. The business’s quarterly revenue was up 16.0% on a year-over-year basis. Sell-side analysts forecast that Sanofi will post 5.07 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.